Population data support use of race (a sociopolitical demographic) in development of prostate cancer risk profiles and screening algorithms. This is "benevolent racial profiling." We should aspire to develop more scientific and objective precision medicine tools to assess risk of clinically significant prostate cancer, such as germline gene testing and assessment of environmental exposures.